About us

Andrew is Chairman of the Board of Oxford Brain Diagnostics (OBD). He is responsible for leading the board and focusing it on strategic matters, overseeing the company’s business and setting high governance standards. 

Andrew is an experienced chairman, company director, and investor in early-stage companies. He now focuses on disruptive software-enabled imaging diagnostics targeted at major healthcare problems. His portfolio includes several successful medical technology startups and he is currently also a director of Intelligent Ultrasound and Founder Director of Brainomix. 

Andrew has more than 30 years experience in public and private high technology companies and brings a wide range of experience in marketing, engineering, acquisitions and fund raising to OBD. He was involved in the early stages of Internet computing in Silicon Valley and later worked to build Intel’s UK venture arm. 

Andrew earned his MBA at the Wharton School of the University of Pennsylvania and holds a BSc (Hons) in Computer Systems Engineering from the University of Kent at Canterbury.

Steven is the Chief Executive Officer and Co-Founder of Oxford Brain Diagnostics (OBD). As a world leading authority on the microstructure of the brain and its altered function in disease, Steven led the creation of Cortical Disarray Measurement (CDM), our unique platform technology for understanding changes in the structure of the brain, while at the University of Oxford. Before leaving the University of Oxford to create OBD, Steven held the position of Associate Professor in Clinical Neurosciences and had more than 20 years of experience researching brain pathology.

After raising seed funding in 2019 he has led the team to deliver our commercial strategy for growth and is responsible for the overall direction of the company. Steven has set a clear vision for OBD and his management team to execute.

During his academic career, Steven held several positions including College Lecturer in Neurology for Medicine at Corpus Christi College, Director of Studies for Human Sciences at Wadham College, culminating in leading his own research group as Associate Professor. In his capacity as principal investigator he won multiple external grants (including from Alzheimer’s Research UK), and was an investigator on several large international projects. He has authored over 40 publications in his respective field in addition to various book chapters, covering topics such as cellular organisation of cerebral cortex, sub-cortical nuclei and tracts, functional correlations, MRI of post-mortem brain, cerebral laterality, comparative brain evolution, and diseases including dementia, schizophrenia and autism.

Steven holds a BSc (Hons), Human Sciences, University College London and a DPhil in Neuroscience, Queen’s College, University of Oxford.

Mark Jenkinson is Professor of Neuroimaging at the University of Oxford, also holding a professorship at the University of Adelaide, Australia. He has extensive research experience in medical image analysis, a world-leading expert on human brain imaging using Magnetic Resonance Imaging (MRI), machine learning and statistical analysis.

At the University of Oxford he leads the structural image analysis group in the FMRIB Centre (since 2003). Mark has a strong track record of developing world-leading image analysis methodology and is a co-founder and the principal developer of the FSL software package, which is the most widely used software package covering the analysis of structural, diffusion and functional MR images of the brain, being used in over 2000 laboratories worldwide. He has been an investigator in major UK and international projects, with total awards over $100 million, including the largest and most cutting-edge multimodal neuroimaging datasets ever assembled – the UK Biobank and the NIH Human Connectome Project. He has over 200 publications with more than 35,000 citations in the last 5 years (and with over 55,000 lifetime citations). He is an invited member of international standardisation committees (INCF Human Atlas Working Group and the NIH Data Format Working Group), co-editor and author of a series of textbooks on neuroimaging analysis, and has been recognized for his work in neuroimaging research by numerous awards, including a David Phillips Fellowship and being listed as a global highly cited researcher for six years.

Ged is the Chief Scientific Officer of Oxford Brain Diagnostics. He has been engaged in medical imaging research and development since 2005, in both academic and commercial settings.

Prior to joining OBD in January 2021, Ged was the Head of Imaging Sciences at Perspectum – an Oxford spin-out applying quantitative MRI to liver diseases. Ged made pivotal technical contributions to two products which received FDA 510(k) clearance: MRCP+, for modelling and quantifying biliary anatomy and disease; and Hepatica, which united Perspectum’s flagship LiverMultiScan technology with volumetric modelling of liver anatomy for applications including surgical planning. Ged had the privilege of taking over from his mentor Professor Sir Michael Brady FRS to lead an outstanding team of imaging scientists whose work was at the core of Perspectum’s innovations.

During his academic career, Ged has co-authored around 80 journal articles, accumulating more than 10,000 citations. His PhD at UCL was supervised initially by Professor Derek Hill, who left to lead Ixico, then by Professor Sebastien Ourselin, with clinical supervision and mentorship throughout from Professor Nick Fox at the Dementia Research Centre. Ged carried out postdoctoral research at the DRC, and the Wellcome Trust Centre for Neuroimaging (the “FIL”), before moving to the Oxford Centre for Functional MRI of the Brain (FMRIB) with a research fellowship. 

Ged holds an MA, MEng from University of Cambridge and a PhD from University College London (UCL). 

Terry is the Chief Operations Officer of Oxford Brain Diagnostics (OBD), also responsible for planning around Finance, Quality & Regulatory, and HR. He was part of the team that worked together for 2 years to create OBD and secure seed funding.

Prior to OBD, Terry worked internationally with colleagues from the University of Oxford to support research organisations in their mission to commercialise disruptive new technologies, providing practical hands-on support to young high-tech start-ups to define a business case and raise funding. Whilst based in Singapore and Malaysia, Terry was able to combine a hectic schedule with opportunities to pursue his passions for travel and photography.

Terry returned to the UK in 2015, settling down in the idyllic town of Royal Leamington Spa. A short train journey to Oxford, he immediately started his search for an opportunity to join a team working to create a new venture with the potential to have a global impact for good.

Whilst searching, Terry mentored young innovators through the Royal Academy of Engineering Leaders in Innovation Fellowship programme and worked with Oxford-based med-tech companies to raise funding and protect their intellectual property. Terry delivered several consulting projects with the National Institute of Health Research (NIHR), allowing him to gain a detailed knowledge of the research infrastructure across the NHS.

Terry holds an MSci in Physics from the University of Bristol and an MBA from Imperial College London Business School. Now working as part of the ambitious and integrated team at OBD, he can combine the latest thinking in business management with the physics mindset of asking lots of questions, taking full advantage of the opportunity to work with our science teams to advance his knowledge of MRI physics and neuroscience.

Mirela provides Quality and Regulatory consultancy services to the Oxford Brain Diagnostics team. With an extensive background in Financial Audit and Procurement for medical devices companies, she started her compliance career over 18 years ago, shifting to medical quality and compliance 7 years ago. Over these 7 years she has worked with multiple medical device companies and has extensive knowledge in quality management systems, as well as US, UK and EU regulations.

Mirela holds a masters degree in Financial audit and a masters degree in Digital Marketing, as well as several quality and compliance certifications.

Mario is a Senior Scientist at Oxford Brain Diagnostics. He is responsible for carrying out scientific  research at the basis of our cortical architecture model and neuroimaging method to support the client projects and the global growth of OBD. He provides measurable performance and quality insights by modeling complex problems understanding cortical dysfunction in Dementias and other neurological conditions. Mario uses cutting-edge approaches to improve understanding of the brain changes behind the earliest stages of neurodegeneration, ageing and other neurological diseases. His different training, skills and experiences, provide a rich source of inspiration for generating new ideas and research questions to improve the scientific background of CDM^® biomarker. 

During his academic career, Mario worked for many years as a Clinical Psychologist and Clinical Research Neuropsychologist with patients suffering from a wide range of psychiatric and neurological disorders. He spent four years at the Neuroimaging Laboratory of Santa Lucia Foundation in Rome, studying the micro and macrostructural brain changes underlying cognitive dysfunctions and behavioural symptoms in Dementia. Mario joined the lab of Neuropathology at the Nuffield Department of Clinical Neurosciences, University of Oxford. He worked for four years with the Dr Steven Chance (CEO & Co-Founder) and Professor Mark Jenkinson (CO-Founder) on developing CDM technology, combining histological, clinical, cognitive behavioural and MRI data (in-vivo and ex-vivo).

Mario holds a BSc in Clinical Psychology, MSc (Hons) in Neuropsychology, University of Palermo. He has a PhD in Neuropsychology at the Catholic University of the Sacred Heart in Rome.

Ian is the Chief Technology Officer of Oxford Brain Diagnostics.  Ian is spearheading OBDs technology strategy  towards cloud automation, designing and building scalable products that address some of the key challenges drug developers and clinicians currently face in Dementia and other Neurological disorders.

Prior to joining OBD, Ian was a highly accomplished entrepreneur, technology designer and systems architect. He was co-founder and CEO of Mode 7 Ltd, an Oxford-based technology and games developer and publisher.  Mode 7 disrupted the online gaming space with their hugely popular "simultaneous turn-based" paradigm, headlined by PC Gamer's Strategy Game of the Year 2011 Frozen Synapse.  They also provided CMS systems used on over 70 television shows on BBC, ITV, Sky, and others, as well as working in the physical interaction space, partnering with Novint Technologies on their motorised input device known as The Falcon.

Omar is the Chief Commercial Officer of Oxford Brain Diagnostics (OBD). He has supported and serviced the pharmaceutical, healthcare and technology sector for over two decades in numerous roles that were transformative.

Prior to joining OBD, Omar held senior executive positions with IQVIA, Ipsos and LOGICACMG. At Ipsos Healthcare he was responsible for the Top 20 Global Accounts Programme along with driving business in Emerging Markets. At IQVIA, he supported and serviced the global pharmaceutical industry for over fifteen years in numerous sales, marketing and general management roles with a focus on commercial effectiveness solutions in emerging geographies to addressing key incentive and performance issues affecting the industry. Prior to that, Omar also worked as a Business Consultant at LOGICACMG. He specialised in wireless technologies, their applications to various business models in Automotive, Healthcare and Defence markets.  His experience exposed him to large Telecom operators like Vodafone, BT Wholesale and T-Mobile.

Omar is client focussed, driven, and passionate about making a difference in Dementia and Neurological disorders. He has excelled in complex large contract value sales, business development, consulting and technology solutions internationally. He thrives on building high performance teams, implementing change and developing talent and expertise to sustain businesses for the long term.

Omar holds a BA (Hons), Business Studies, University of East London, and an MBA from Bayes Business School, London specialising in Strategic Management of Technology.

Michele joined Oxford Brain Diagnostics as Junior Software Engineer and Data Scientist in 2020. He is responsible for the development of the CDM^® technology, working with both the science and technology teams to support client projects and continue to build biomarker and diagnostic products for Dementia and Neurological disorder markets. Michele is honoured to join the fight against Dementia at Oxford Brain Diagnostics, and to apply his skills to make a difference in such a vital field, where he believes that technology can significantly improve the lives of patients.

Prior to joining OBD, Michele worked for the Boston Consulting Group in Milan, Italy. His focus was working with proprietary algorithms to supply clients with predictive analytics of future sales margins. Michele undertook an internship with the Computer Science department, where he was tasked with automating the movement of a robot using brain stimuli inputs. After winning a competition for his work during the internship, Michele completed a Master’s thesis which focused on computer simulations of quantum dynamics.

Michele holds an MSc, Physics from Durham University.

Jamie is a Junior Software Engineer and Data Scientist. He has a passion for where neuroscience and technology meet and has a background in smartphone healthcare applications.

At OBD, he works within the technology team, developing new ideas, analysing, and processing new project data and supporting the science team in analysis and new investigations.

Prior to joining OBD, Jamie worked at a start-up focussing on smartphone healthcare applications, working within the research and development team whose goal it was to measure and monitor various metrics about the user such as blood sugar levels and many aspects of cardiovascular health. His academic background includes medical engineering with a neurotechnology focus, with dissertations on brain segmentation in new-borns and the flow of solutes in the brain vessel network known as the glymphatic system.

Jamie holds a BEng (Hons) in Medical Engineering from Cardiff University and a MSc in Biomedical Engineering (Neurotechnology) from Imperial College London.

Daniel is a Business Development Advisor of Oxford Brain Diagnostics. He was part of the team that worked together for 2 years to create OBD and secure seed funding. Passionate about ESG (environmental, social, governance) issues, Daniel specializes in high tech commercialization strategy and implementation, with focus on med tech and clean tech. His extensive scientific/academic and business/commercial networks allow him to pull together the right resources for pushing forward and successfully bringing into fruition highly technical projects. He believes it is possible to create systems and technologies which better serve patients and society and is involved with the NHS Patient Public Involvement (PPI).  Daniel has two decades of successful start-up business experience and is passionate about bringing people together to succeed.

Daniel broke four generations of family tradition by not becoming a medical doctor and choosing to study materials engineering science instead, receiving his Ph.D. at Cambridge University. He studied engineering with a double diploma (with distinction) from Ecole Centrale de Paris, France, and University of Stuttgart, Germany; is fluent in English, French, German and Russian. Until February of 2015 he headed the Oxford and Cambridge Society of Toronto. With over 2,000 members and 80 events annually, it is still one of the most active societies in North America. While under his leadership, membership expanded exponentially and started funding scholarships to Oxford and Cambridge. He is also mentoring students and start-ups in Oxford and Cambridge, and loves hiking, cycling, history and politics.

Jeffrey Cummings, MD, ScD, is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). 

Dr. Cummings is globally recognized for his contributions to Alzheimer’s research, drug development, and clinical trials.  He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association (2019), and the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.” 

Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.  He has authored or edited 43 books and published over 800 peer-reviewed papers. 

Dr Lynne Hughes is an international neurology clinical trial research expert and brings with her 35 years of experience in the global clinical research field. Previously, Lynne was Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as a program director and also from the design perspective – working with clients to develop evidence-based strategies for the most efficient conduct of clinical development plans. She provided consultancy advice in Alzheimer’s disease (AD), Parkinson’s disease, pain indications, multiple sclerosis, acute care including TBI and stroke, migraine and epilepsy and a range of neuro-orphan indications.

Lynne has a particular interest in neurocognitive assessment and design of appropriate studies to assess AD & neurocognitive dysfunction and is a member of many steering and / or executive committees. Lynne is a current member of the NIA-NIH task force for recruitment into AD trials and development of the US National Framework and is co-chair of the DAVOS (DAC) taskforce for expediting clinical AD trials, sponsored by WEF & CEOi. She is also a member of the G7 & G20 World Dementia Councils.